LINICAL HARMACOLOGY % "THERAPEUTICS EDITOR Marilynn C. Frederiksen, MD C. Michael Stein. MD Kathleen Giacomini, PhD Jean Gray, MD, FRCP(¢ EDITOR EMERITUS Linda E Gustavson, PhD Marcus M. Reidenberg, MD Perry V. Halushka, MD, PhD : Chomas K. Henthorn, MD FOUNDING EDITOR roe ; peter ts iD Walter Modell, MD (Deceased an ae raki, MD ASSOCIATE EDITORS William J Arthur J. Atkinson, Jr, MD Shigeru Kageyama Richard B. Kim, MI Helen Kastrissios. Ph] David W. Nierenberg, MD Joan M. Korth-Bradle Grant R. Wilkinson, PhD EDITORIAL BOARD David Li oweCewinlts,h ailv.il MD l Darrell R. Abernethy, MD, PhD Carl V. Manion, MD \deday O \ded VIN, Phi Edward B. Nelson, MD Matthew M. Ames, PhD Michael C. Orme, MB, BS Fred Y. Aoki, MD Russell K. Portenoy, MD Glen Apseloftt, MD William Z. Potter, MD, PhD Larry A. Bauer, PharmD Mark J. Ratain, MD Leif Bertilsson, PhD Mary V. Relling, PharmD Terrence F. Blaschke, MD Janice B. Schwartz, MD 2. A. Branch, MD Edward M. Sellers, MD, PhD, FRCP(¢ sric P. Brass, MD, PhD Steven L. Shafer, MD ). Craig Brater, MD ewis B. Sheiner, MD \lastair Breckenridge, MSc, MD Alexander M. M. Shepherd, MD, PhD Jouwe D. Breimer, PhD Sang-Goo Shin, MD, PhD Michael E. Brier, PhD Daniel S. Sitar, PhD ames F. Burris, MD Folke Sjéqvist, MD, PhD S. George Carruthers, MD, FRCP Donald R. Stanski, MD Dennis J. Chapron, RPh, MS Arnold B. Sterman, MD David M. Cocchetto, PhD John T. Sullivan, MB, ChB, FRACP C. Lindsay DeVane, PharmD Robert Temple, MD lin Dollery, MB, ChB, BSc Andre Terzic, MD, PhD garet S. Dordal, MD, PhD Timothy S. Tracy, PhD \kio Ebihara, MD Elliot S. Vesell, MD David J. Edwards, PharmD Robert E. Vestal, MD Merrill J. Egorin, MD John B. Warren, MD, FRCP Thomas Eissenberg, PhD William B. White, MD William E. Evans, PharmD John T. Wilson, MD Ross D. Feldman, MD Alastair J. J. Wood, MB, ChB Charles Flexner, MD Raymond L. Woosley, MD, PhD VOLUME 73, JANUARY-JUNE 2003 MOSBY, INC, ST LOUIS LINICAL HARMACOLOGY e THERAPEUTICS Official Publication of the American Society for Clinical Pharmacology and Therapeutics American Society for Pharmacology and Experimental Therapeutics EDITORIAL COMMITTEE FOR THE JOURNAL D. Craig Brater, MD, Indianapolis, Ind (ASCPT) Alastair J. J. Wood, MD, Nashville, Tenn (ASCPT) Scott A. Waldman, MD, PhD, Philadelphia, Pa (ASCPT) Perry V. Halushka, MD, PhD, Charleston, SC (ASPET) Darrell R. Abernethy, MD, PhD, Baltimore, Md (ASPET) Gregory L. Kearns, PharmD, Kansas City, Mo (ASCPT) Barbara A. Levey, MD, FACP, Los Angeles, Calif (ASCPT) John J. Schrogie, MD, King of Prussia, Pa (ASCPT) OFFICERS OF THE AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS President: Gregory L. Kearns, PharmD, PhD, Kansas City, Mo President-Elect: Andre Terzic, MD, PhD, Rochester, Minn Secretary-Treasurer: John J. Schrogie, MD, King of Prussia, Pa Chair, Editorial Committee: D. Craig Brater, MD, Indianapolis, Ind Executive Director: Sharon J. Swan, CAE, Alexandria, Va MEMBERS OF THE COUNCIL OF THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS President: Paul F. Hollenberg, PhD, Ann Arbor, Mich President-Elect: David B. Bylund, PhD, Omaha, Neb Secretary-Treasurer: James E. Barrett, PhD, Montvale, NJ Chair, Board of Publications Trustees: Brian M. Cox, PhD, Bethesda, Md Executive Officer: Christine K. Carrico, PhD, Bethesda, Md Volume 73 Copyright © 2003 by the American Society for Clinical Pharmacology and Therapeutics All rights reserved Printed in the United States of America Author index Abdel-Rahman SM (see Lowry et al AbeRl (sse e Noel et 2003;73:292 Aberg JA (see Washington et < Adams J (see Klinkhard Adedoyin A (see Carcill AIDS Clinical Trials ¢ ol 37 see Washington et 406-16 AIDS Clinical Tria see Hamzeh et 159-69 Al-Dam A ( Andersson K (se Atkinson AJ Ayan-Oshodi M ( Backman JT Backman JT Badner J DG, D bitors of Barst RJ, Ivy D, Ding Nguyen N, Gaitonde M, vz rsbergen PLM. Pharmacoki and efficacy of boser yn. 2003:73 Bauersach (see Klinkhar Baughman SA Bebia Z | Becker M (see Dor > et al). 2003;73:78-86. Correction 2003;73:576 Cook It e Saw Becquemont é orstuy t al) 3:73:51-60 Cooper KJ. Martin PI Begg EJ (see Gardine 71-7 | Bend JR (see Bailey Hamzeh et al). 2003 T Voelker JR.> Teriparatide f =p harmacodysri namics of digoxin.Se 2003; 7 Bertilsson L (see Christensen et al). 2003 Bertino JS Jr (see Lowry et al). 2003:7 Bertino JS Jr (see Rogers et al). 2003;7 3ingaman D (see Barst et al). 2003;7 Biollaz J (see Csajka et al). 2003:7 Blaschke TF (see Washington et al 3ockbrader H (see Mill Boyett J (see Dervieux et al) 3oyett JM (see Sawyer et al). 2003;7 3radford LD (see Gaedigk et al). 2003;73:575-6 _ 3ranch RA (see Carcillo et al). 2003:73:456-67 e Hoog Mouton JW 3rass EP, Mayer MD, Mulford DJ, Stickler TK, Hoppe carnitine homeostasis of short-term treatment with the cefditoren pivoxil. 2003;73 srdutigam L (see T sriglia AE (see Dowli 3rinkmann U (see Verstuyft et al). 2003;73:5 3uclin T (see Csajka et al). 2003:73:20-30 BurckGaJr (tse e Cz t al). 2003;7 Burger P (see¢ 3urhenne J ( 146; February, pp. P1 480; June, pp 1 the February issue CLINICAL PHARMACOLOGY & THERAPE CLINICAL PHARMACOLOGY & THERAPEUTICS 580 Author index JUNE 2003 Ding R (see Tayrouz et al). 2003;73:397-405 Goodman DB (see Noel et al). 2003;73:292-303 Dingemanse J (see Barst et al). 2003;73:372-82 Graff J (see Klinkhardt et al). 2003;73:232-41 Dishy V (see Sofowora et al). 2003;73:366-71 Grass P (see Comets et al). 2003;73:95-106 Donahue JP, Dowdy D, Ratnam KK, Hulgan T, Price J, Unutmaz D, Nicotera Greim C (see Wagner et al). 2003;73:272-4 (Letter) J, Raffanti S, Becker M, Haas DW. Effects of nelfinavir and its M8 Guillaume C (see Stolk and Guillaume). 2003;73:131 (Letter) metabolite on lymphocyte P-glycoprotein activity during antiretroviral Gupta SK (see Kang et al). 2003;73:31-40 therapy. 2003;73:78-86. Correction 2003;73:576 Gurwitz JH (see Simon and Gurwitz). 2003;73:387-93 (Commentary) Doran A (see Barst et al). 2003;73:372-82 Dowdy D (see Donahue et al). 2003;73:78-86. Correction 2003;73:576 H Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL. Characterization of Haas DW (see Donahue et al). 2003;73:78-86. Correction 2003;73:576 hepatic cytochrome P4503A activity in patients with end-stage renal dis- Haefeli WE (see Tayrouz et al). 2003;72:397-405 ease. 2003;73:427-3 Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJL, Kamath BL, 1: effects on response to aspirin. 2003;73:122-30 Rettie AE. Cytochrome P4502CP activity in end-stage renal disease. 2003; Halushka PV (see Halushka et al). 2003;73:122-30 73:475-7 (Letter) Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu Drescher S, Glaeser H, Miirdter T, Hitz] M, Eichelbaum M, Fromm MF H, Lee J, Flexner C, AIDS Clinical Trials Group 365 Study Team P-glycoprotein—mediated intestinal and biliary digoxin transport in hu- Steady-state pharmacokinetic interaction of modified-dose indinavir and mans. 2003;73:223-31 rifabutin. 2003;73:159-69 Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of Hancock ML (see Dervieux et al). 2003;73:506-16 both cytochrome P4503A and MDRI1 by St John’s wort in healthy subjects. Hanes DS (see Dowling et al). 2003;73:427-34 2003;73:41-50 Harder S (see Klinkhardt et al). 2003;73:232-41 Dresser GK (see Bailey et al). 2¢ Harris PA (see Sofowora et al). 2003;73:366-71 Dubert L (see Verstuyft et al) Haruyama H (see Watanabe et al). 2003;73:435-55 Haughey DB (see Rogers et al). 2003;73:153-8 (Commentary) Hebert MF (see Park et al). 2003;73:543-53 Heide L (see Wagner et al). 2003;73:272-4 (Letter) Echizen H (see Takahashi et al). 2003;73:253-63 Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and Eddington ND (see Dowling et al). 2003;73:427-34 norfluoxetine in pregnancy and lactation. 2003;73:330-7 Eichelbaum M (see Drescher et al). 2003;73:223-31 Henrich WL (see Dowling et al). 2003;73:427-34 Ekblad U (see Heikkinen et al). 2003;73:330- Hermann R, Ferron GM, Erb K, Knebel N, Ruus P, Paul J, Richards L, Cnota El Morabet H (see Verstuyft et al). 2003;73:51-60 H-P, Troy S. Effects of age and sex on the disposition of retigabine Erb K (see Hermann et al). 2003;73:61-70 2003;73:61-70 Evans WE (see Dervieux et al). 20032;.7923 :506-16 Higuchi S (see Nishizato et al). 2003; Hirota T (see Nishizato et al). 2003;73:5: FE Hitzl M (see Drescher et al). 2003;7 Hoffer C (see Kharasch et al). 2003; Fattinger K (see Csajka et al). 2003;73:20-30 Hoppel CL (see Brass et al). 2003;73:338-47 Fellay J (see Csajka et al). 2003;73:20-30 Hoppe-Tichy T (see Tayrouz et al). 2003;73:397-405 Ferron GM (see Hermann et al). 2003;73:61-70 Horsmans Y (see Chalon et al). 2003;73:178-91 Fink JC (see Dowling et al). 2003;73:427-34 Huang S-L (see Chen et al). 2003;73:264-71 Flexner C (see Hamzeh et al). 2003;73:159-69 Huang Z (see Chen et al). 2003;73:264-71 Flexner C (see Washington et al). 2003;73:406-16 Hulgan T (see Donahue et al). 2003;73:78-86. Correction 2003;73:576 Frame B (see Miller et al). 2003;73:491-505 Hunt TL (see Noel et al). 2003;73:292-3¢ Fromm MF (see Drescher et al). 2003;73:22 Frye RF (see Carcillo et al). 2003;73:456-67 Frye RF (see Chalon et al). 2003;73:178-91 I Funck-Brentano C (see Démolis et al). 2003;73:2 2 leiri I (see Nishizato et al). 2003;73:554-65 Funck-Brentano C (see Verstuyft et al). 2003;73:51-60 Innocenti F (see Sawyer et al). 2003;73:566 Furukawa H (see Watanabe et al). 2003:73:435-55 Irie S (see Nishizato et al). 2003; 3:554-65 Ivy D (see Barst et al). 2003;73:372-82 Izumi T (see Watanabe et al). 2003;73:435-55 G Gaedigk A, Ndjountché L, Gaedigk R, Bradford LD, Leeder JS. Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in Afri- can American subjects. 2003;73:575-6 (Letter) Jaillon P (see Verstuyft et al). 2003;73 Gaedigk R (see Gaedigk et al). 2003;73:575-6 (Letter) Japa S (see Dreisbach et al). 2003;73:475-7 (Letter) Gaitonde M (see Barst et al). 2003; 25 .299.2-26929 Jénsson S, Karlsson MO. A rational approach for selection of optimal Gardiner SJ, Kirkpatrick CMJ, Begg EJ, Zhang M, Moore MP, Saville DJ covariate-based dosing strategies. 2003;73:7-19 Transfer of metformin into human milk. 2003;73:71 Garnick MB (see Wong et al). 2003;73:304-11 Garofalo E (see Miiler et al). 2003; 491-505 K Gebrekal AB (see Dreisbach et al). 2003;73:475-7 (Letter) Kalhorn TF (see Park et al). 2003;73:543-53 Geisslinger G (see Skarke et al). 2003;73:10 Kalow W. Medical practice, race, and drug use. 2003;73:132-4 (Letter) Geisslinger G (see Tegeder et al). 2003;7 3:417-26 Kamath BL (see Dreisbach et al). 2003;73:475-7 (Letter) Gerber J (see Hamzeh et al). 2003;73:159-69 Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB Glaeser H (see Drescher et al). 2003;73:2 ~» 3-3] Population analyses of sustained-release verapamil in patients: effects of Gleiter CH (see Wagner et al). 2003; 72.999 4 (Letter) sex, race, and smoking. 2003;73:31-40 Golnez J-L (see Chalon et al). 2003;73:178-91 Karlsson MO (see Jonsson and Karlsson). 2003;73:7-19 Gonzales CR (see Skinner et al). 2003;73:170-7 Karyekar CS (see Dowling et al). 2003;73:427-34 CLINICAL PHARMACOLOGY & THERAPEUTICS VOLUME 73, NUMBER 6 Author index 581 Kashima T (see Takahashi et al). 2003;73:253-63 1 potential model substrate to assess cytochrome Kashuba ADM (see Lowry et al). 2003;73:2 2 2003;73:209-22 Kawabata K (see Nishizato et al). 2003;73:554-65 Luurila H (see Li Kawai R (see Comets et al). 2003:73:95 Kawano T (see Obase et al). 2003;73:468-74 Kearns GL (see Koren et al). 2003:73:!47-52 (Commentary) Kearns GL (see Lowry et al). 2003:73:209-22 Marbach P (see Comets Kerb R (see Verstuyft et al). 2003;73:51-60 Marsh CL (see Park et al Khan IS (see Lowry et al). 2003;73:209-22 Martin PD (see C Kharasch ED, Hoffer C, Walker A, Sheffels P. Disposition and miotic effects Marzolini C (se alfentanil: a potential noninvasive probe for first-pass cytochrome Matsuse H (see 2003:73:199-208 Matsushita Y Kim RB (s > st al). 2003:73 Mayer MD (see Kim RB (se ora et al). 2003:73 7 McCrea J (see Hamzeh et a Kim RB (sé al ta 73:2 93 Menchaca D (see Wong et al) Kim RB (see Wandel et a :73:394-6 (Commentary) nti (see Comets et Kimko HC (see Lee et al 73:348-65 Kimura M (see Nishizato et al). 2003;73:554 Kimura S (see Takahashi et < Kinoshita M (see Obase « ) 3:73:468 Kirkpatrick CMJ (see st al). 2003:73:7 Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Lz tin expre ith atherosclerotic Skinner fermann et ¢ 003:7 70 lowry see Dreisbach et al KnollC ( arcillo et al). 2003:73:456-6 Muirheac (see Christensen Koga T (see Watanabee t al ‘73:43 5 ilder van den Bergh FAJTM, Vermes I. Response t Kohno §S (see Obase et al 73 14 imvastatin 1 e polymorpt Koishi R (see Watanabe et Koren G, Kearns GI in drug 2s: the ethical debate 3;73:147-52 (Commentary Kovacs AF Krecic-Shepard ME Ku e Skinner et al). 2003;73 Kusuhara H (see hizato et al). 2003;7 Kyrklund C, Backman JT, Neuvonen M 2003 et al). 2003;73 x MM. What has been the > uurila H nen raconazole decreases plasma con rations of hardt et 20039 6tsch J (see Skarke et al). 2003 owry JA, Kearns GL, Abdel-Rahman ADM, Schuetz EG, Bertino JS Jr CLINICAL PHARMACOLOGY & THERAPEUTICS 582 Author index JUNE 2003 Pantle-Fisher FH (see Sawyer et al). 2003;73:566-74 Schmitt K (see Barst et al). 2003;73:372-82 Park JM, Lin YS, Calamia JC, Thummel KE, Slattery JT, Kalhorn TF, Car- Schneck DW (see Cooper et al). 2003;73:322-9 ithers RL Jr, Levy AE, Marsh CL, Hebert MF. Transiently altered acet- Schuetz EG (see Lowry et al). 2003;73:209-22 aminophen metabolism after liver transplantation. 2003;73:543-53 Schwartz JB (see Kang et al). 2003;73:31-40 Paul J (see Hermann et al). 2003;73:61-70 Schwarz UI (see Dresser et al). 2003;73:41-50 Peck CC, Rubin DB, Sheiner LB. Hypothesis: a single clinical trial plus causal Scientific Organizing Committee and Conference Report Committee (see Rolan evidence of effectiveness is sufficient for drug approval. 2003;73:481-90 et al). 2003;73:284-91 (Commentary) (Commentary ) Seegel M (see Tegeder et al). 2003;73:417-26 Peck CC (see Lee et al). 2003;73:348-65 Segal Y (see Washington et al). 2003;73:406-16 Pei D (see Sawyer et al). 2003;73:566-74 Sereika S (see Carcillo et al). 2003;73:456-67 Pickkers P (see de Hoon et al). 2003;73:312-21 Sheffels P (see Kharasch et al). 2003;73:199-208 Pons G (see Koren et al). 2003;73:147-52 (Commentary) Sheiner LB (see Peck et al). 2003;73:481-90 (Commentary) Prasad HC (see Sofowora et al). 2003;73:366-71 Sheiner LB (see Washington et al). 2003;73:406-16 Price J (see Donahue et al). 2003;73:78-86. Correction 2003:73:576 Shimizu M (see Watanabe et al). 2003;73:435-55 Pui C-H (see Dervieux et al). 2003; 3:506-16 Shimoda T (see Obase et al). 2003;73:468-74 Simon SR, Gurwitz JH. Drug therapy in the elderly: improving quality and Q access. 2003;73:387-93 (Commentary) Skarke C, Darimont J, Schmidt H, GeisslingeGr, Lotsch J. Analgesic effects of Quick JD. Ensuring access to essential medicines in the developing countries: morphine and morphine-6-glucuronide in a transcutaneous electrical pain a framework for action. 2003;73:279-83 (Commentary) model in healthy volunteers. 2003;73:107-21 Skinner MH, Kuan H-Y, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo R KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers Raffanti S (see Donahue et al). 2003;73:78-86. Correction 2003;73:576 2003;73:170-7 Rajpal A, Reidenberg MM. Drug labeling should be kept current. 2003;73:4-6 Slattery JT (see Park et al). 2003;73:543-53 (Commentary) Smith BP (see Chalon et al). 2003;73:178-91 Ramirez J (see Sawyer et al). 2003;73:566-74 Smits P (see de Hoon et al). 2003 3:312-21 Ratain MJ (see Sawyer et al). 2003;73:566-74 Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, Prasad HC, Ratnam KK (see Donahue et al). 2003;73:78-86. Correction 2003;73:576 Byrne DW, Nair UB, Wood AJJ, Stein CM. A common £,-adrenergic Reddy S (see Skinner et al). 2003;73:170- receptor polymorphism (Arg389Gly) affects blood pressure response to Reed M (see Koren et al). 2003;73:147-52 (Commentary) B-blockade. 2003;73:366-71 Reidenberg JW. The need to consider the cost factor of drugs in clinical trials. Stackiewicz L (see Dowling et al). 2003;73:427-34 2003;73:477-8 (Letter) Stein CM. Clinical Pharmacology & Therapeutics—an update. 2003;73 Reidenberg MM (see Levy and Reidenberg). 2003;73:275-8 (Commentary) (Commentary) Reidenberg MM (see Rajpal and Reidenberg). 2003;73:4-6 (Commentary) Stein CM (see Sofowora et al). 2003;73:366-71 Relling MV (see Dervieux et al). 2003;73:506-16 Stein CM (see Wandel et al). 2003;73:394-6 (Commentary) Rettie AE (see Dreisbach et al). 2003;73:475-7 (Letter) Stickler TK (see Brass et al). 2003:73:338-47 Ribeiro RC (see Dervieux et al). 2003;73:506-16 Stolk LM, Guillaume C. Routine early therapeutic drug monitoring is necessary Richards L (see Hermann et al). 2003;73:61-70 during the first week of life. 2003;73:131 (Letter) Riedel K-D (see Tayrouz et al). 2003;73:397-405 Strabach S (see Verstuyft et al). 2003:73:51-60 Rivera GK (see Dervieux et al). 2003;73:506-16 Struijker-Boudier HAJ (see de Hoon et al). 2003;73:312-21 Rocci ML Jr (see Rogers et al). 2003;73:153-8 (Commentary) Sugawara M (see Watanabe et al). 2003;7 3:-435-55 Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. An evaluation of the Sugiyama Y (see Nishizato et al). 2003;73:554-65 suitability of intravenous midazolam as an in vivo marker for hepatic Suzuki H (see Nishizato et al). 2003:73:554-65 cytochrome P4503A activity. 2003;73:153-8 (Commentary) Rogge M (see Lee et al). 2003;73:348-65 T Rolan P, Atkinson AJ Jr, Lesko LJ, Scientific Organizing Committee and Conference Report Committee. Use of biomarkers from drug discovery Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, through clinical practice: report of the Ninth European Federation of Kimura S, Echizen H. Population differences in S-warfarin metabolism Pharmaceutical Sciences Conference on Optimizing Drug Development between CYP2C9 genotype—matched Caucasian and Japanese patients 2003;73:284-91 (Commentary) 2003;73:253-63 Romkes M (see Carciilo et al). 2003;73:456-67 Takahashi T (see Watanabe et al). 2003;73:435-55 Rosenkranz SL (see Washington et al). 2003;73:406-16 Takane H (see Nishizato et al), 2003;7 3:554-65 Roskos L (see Carcillo et al). 2003;73:456-67 Tan Z-R (see Chen et al). 2003;73:264-71 Ruan P (see Hamzeh et al). 2003;73:159-69 Tayrouz Y, Ding R, Burhenne J, Riedel K-D, Weiss J, Hoppe-Tichy T, Haefeli Rubin DB (see Peck et al). 2003;73:481-90 (Commentary) WE, Mikus G. Pharmacokinetic and pharmaceutic interaction between Ruus P (see Hermann et al). 2003;73:61-70 digoxin and Cremophor RH40. 2003>; 73:397-405 Tegeder I, Bréutigam L, Seegel M, Al-Dam A, Turowski B, Geisslinger G, Kovacs AF. Cisplatin tumor concentrations after intra-arterial cisplatin Nn infusion or embolization in patients with oral cancer. 2003;73:417-26 Saeki S (see Obase et al). 2003:73:468-74 Telenti A (see Csajka et al). 2003:73:20-30 Sandlund JT (see Dervieux et al). 2003;73:506-16 Thomasson HR (see Chalon et al). 2003;73:178-91 Sathirakul K (see Skinner et al). 2003;73:170-7 hummel K (see Carcillo et al). 2003;73:456-67 Sauer J-M (see Chalon et al). 2003;73:1l7 8-91 Thummel! KE (see Park et al). 2003;7 3:543-53 Saville DJ (see Gardiner et al). 2003; 7371-7 Tomari S-y (see Obase et al). 2003;7 3:468-74 Sawyer MB, Innocenti F, Das S, Cheng C, Ramirez J, Pantle-Fisher FH, Wright Tomita A (see Watanabe et al). 2003:73:435-55 C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ. A pharmacogenetic Troy S (see Hermann et al). 2003;73:61-70 study of uridine diphosphate-glucuronosyltransferase 2B7 in patients re- Trugnan G (see Verstuyft et al). 2003;73:51-60 ceiving morphine. 2003;73:566-74 Turowski B (see Tegeder et al). 2003;73:417-26 Schmidt H (see Skarke et al). 2003;73:107-21 Tybring G (see Christensen et al). 2003;73:517-28 CLINICAL PHARMACOLOGY & THERAPEUTICS VOLUME 73, NUMBER 6 Author index 583 L Team. Effect of simultaneous versus staggered dosing on phz Unutmaz D (see Donahue et al). 2003;73:78-86. Correction 2003:7 interactions of protease inhibitors. 2003;73:406-16 Urae A (see Nishizato et al). 2003;73:554-65 Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Urasaki Y (see Nishizato et al). 2003;73:554-65 Takahashi T, Miyoshi K, Nakamura K, Izumi T, Matsushita Y H, Haruyama H, Koga T. As tudy to survey susceptible geneti responsible for troglitazone-associated hepatotoxicity in Japanese V with type 2 diabetes mellitus. 2003;7 Vacheron F (see Démolis et al). 2003;73 Weir see Dowling et al). 2003;7 Van Bortel LMAB (see de Hoon et al) Weiss J (see Tayrouz et al). 2¢ )3°7 van den Anker JN (see de Hoog et 2003;73:131-2 (Letter reply) Widlitz A (see Barst et al). 2003 van den Anker JN (see Lowry et al). 2003;73:2 Wilkinson GR (see Dresser et a van den Bergh FAJTM (see Mulder et al). 2003;73:475 (Letter) Wilkinson GR (see Takahashi et al )3 253-63 van Giersbergen PLM (see Barst et al). 2003; 2:95 Wilson JW (see Carcillo et al). 2003:73:456-67 Venkataramanan R (see Carcillo et al). 2003;73:456-6 Wise SD (see Skinner et al). 2003;73 Vermes I(see Mulder et al). 2003;73:475 (Letter) Witcher J (see Chalon et al). 2003 178-9 Verotta D (see Kang et al). 2003;73:31-40 Wong SL, Lau DT-W, Baughman SA, Menchaca D, Garnick MB Verstuyft C, Strabach S, El Morabet H, Kerb R, Brinkmann U, Dubert | kinetics and pharmacodynamics of abarelix, a gonadotropin-releasing | Jaillon P, Funck-Brentano C, Trugnan G, Becquemont L. Dipyridamole mone antagonist, after subcutaneous continuous infusion in | enhances digoxin bioavailability via P-glycoprotein inhibition. 2003; prostate cancer. 2003;73 51-60 Wood AJJ (see Sofowora et al). 2003;73:366-71 Verweij J. Concern about similarity of manuscripts. 2003;73:274 (Letter Wright C (see Sawyer et al). 2003;73:566-74 Voelker JR (see Benson and Voelker). 2003;73:87-94 Wu H (see Hamzeh et al). 2003;7 Vonderscher J (see Comets et al). 2003:73:95-106 W Wagner I, GreimC , Laufer S, Heide L, Gleiter CH. Influence of willow extract on cyclooxygenase activity and on tumor necrosis factor a or interleukin 18 release in vitro and ex vivo. 2003;73 4 (Letter) Wahlberg A (see Christensen et al). 2003;73 Walker A (see Kharasch et al). 2003;73:199-2 Yasar U (see Christensen et al). 2003;7 Walker LP (see Halushka et al). 2003;73:122 Yasumo H (see Watanabe et al). 2003;7 Wandel C, Kim RB, Stein CM. “Inactive is Cremophor Yeo KP (see Skinner et al 3;73:1 affect in vivo drug disposition. 2003 » (Commentary Wang D (see Lee et al). 2003;73 Warwick MJ (see Cooper et al) Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA Zhang M (see Gardiner et al) Blaschke TF, AIDS Clinical Trials Group Protocol 378 (ACTG 378) Study Zhou H-H (see Chen et a Subject index Aspirin Clopidogrel but not aspirin reduces P-selectin expression and formation of A barelix platelet-leukocyte aggregates in patients with atherosclerotic vascular Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin disease (Klinkhardt et al). 2003;73:232-41 easing hormone antagonist, after subcutaneous continuous infusion Genetic variation in cyclooxygenase 1: effects on response to aspirin in patients with prostate cancer (Wong et al). 2003;73:304-11 (Halushka et al). 2003;73:122-30 Abstracts Isozyme-specific induction of low-dose aspirin on cytochrome P450 in Abstracts. 2003;73:P 1-126 healthy subjects (Chen et al). 2003;73:264-71 Accessibility to health services; see Health services accessibility Asthma Acetaminophen Polymorphisms in the CYP/JA2 gene and theophylline metabolism in Transiently altered acetaminophen metabolism after liver transplantation patients with asthma (Obase et al). 2003;73:468-74 Park et al). 2003;73:543-53 Atherosclerosis Acromegaly Clopidogrel but not aspirin reduces P-selectin expression and formation of Population pharmacodynamic analysis of octreotide in acromegalic pa- platelet-leukocyte aggregates in patients with atherosclerotic vascular tients (Comets et al). 2003;73:95-106 disease (Klinkhardt et al). 2003;73:232-41 Administration, oral Atomoxetine Disposition and miotic effects of oral alfentanil: a potential noninvasive Effect of hepatic impairment on the pharmacokinetics of atomoxetine and probe for first-pass cytochrome P4503A activity (Kharasch et al) its metabolites (Chalon et al). 2003;73:178-91 2003:73:199-208 African Americans B Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects (Gaedigk et al). 2003;73 Bergamottin Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 Age facto5r7s5 6 (Letter) 3A4 activity: comparison with grapefruit juice (Bailey et al). 2003;73 Effects of and sex on the disposition of retigabine (Hermann et al 529-37 2003:7 Beta adrenergic receptors; see Receptors, adrenergic, beta Beverages in the elderly: improving quality and access (Simon and Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 Gurwitz). 2003;73:387-93 (Commentary) 3A4 activity: comparison with grapefruit juice (Bailey et al). 2003;73 Alfentanil 529-3 Disposition and miotic effects of oral alfentanil: a potential noninvasive Itraconazole increases but grapefruit juice greatly decreases plasma con probe for first-pass cytochrome P4503A activity (Kharasch et al) centrations of celiprolol (Lilja et al). 2003;73:192-8 2003:73:199-208 Biliary tract Alleles P-glycoprotein—mediated intestinal and biliary digoxin transport in humans Discovery of a novel nonfunctional cytochrome P450 2D6 allele, (Drescher et al). 2003;73:223-31 CYP2D6*42 in African American subjects (Gaedigk et al). 2003;73 Biological availability 575-6 (Letter) Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibi American Society for Clinical Pharmacology and Therapeutics tion (Verstuyft et al). 2003;73:51-60 from the ASCPT membership committee chairperson. 2003; Biomarkers Use of biomarkers from drug discovery through clinical practice: report of sssage from the ASCPT membership committee chairperson. 2003 the Ninth European Federation of Pharmaceutical Sciences Conference 19-80 on Optimizing Drug Development (Rolan et al). 2003;73:284-91 2003 Annual Meeting Program. 2003;73:136-46 (Commentary ) Analgesia Blood platelets Analgesic effects of morphine and morphine-6-glucuronide in a transcu Clopidogrel but not aspirin reduces P-selectin expression and formation of taneous electrical pain model in healthy volunteers (Skarke et al) platelet-leukocyte aggregates in patients with atherosclerotic vascular 2003: : disease (Klinkhardt et al). 2003;73:232-41 Anti-infective agents, fluoroquinolone Blood pressure Effects of three fluoroquinolones on QT interval in healthy adults after A common £,-adrenergic receptor polymorphism (Arg389Gly) affects single doses (Noel et al). 2003;73:292-303 blood pressure response to B-blockade (Sofowora et al). 2003;73 Antihypertensive agents 366-7 | Drug labeling should be kept current (Rajpal and Reidenberg). 2003;73:4-6 Books (Commentary ) Books received. 2003;7 Antiviral agents Bosentan Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients activity during antiretroviral therapy (Donahue et al). 2003;73:78-86 with pulmonary arterial hypertension (Barst et al). 2003;73:372-82 Correction 2003;73:576 Breast feeding Transfer of metformin into human milk (Gardiner et al). 2003;73:7 January, pp. 1-146; February, pp. P1-P126; March, pp. 147-274; April, pp Caffeine 275-386; May, pp. 387-480; June, pp. 481-590. Index to the ASCPT meeting The Karolinska cocktail for phenotyping of five human cytochrome P450 abstracts is located in the February issue enzymes (Christensen et al). 2003;73:517-28 584 JUNE 2003 CLINICAL PHARMACOLOGY & THERAPEUTICS CLINICAL PHARMACOLOGY & THERAPEU rics Subject index 585 VOLUME 73, NUMBER 6 ‘alcitonin gene-related peptide Cyclosporine Calcitonin gene-related peptide: exploring its vasodilating mechanism of ff both cytochro action in humans de Hoon et al). 206 3:7 ‘alcium Teriparatide has no effec t on the calcium-mec iated pharmacodynamics of digoxin (Benson and Voelker 2003:7 arnitine 529-3 Impact on carnitine homeostasis of short-term “haracterizatio prodrug cefditoren piv astor oil ‘Inactive’ excipients such as Cremophor tion (Wandel et al). 2003;73:394 C mophor RH40 (Tayrouz et al ‘aucasian Americans; see White Americans 1 hneeaalitthhyy ausality Hypothesis: a le clinical tr sufficient for drug ‘efditoren CYP2D6*42. Impact on carn > home 575-6 (Letter prodrug cefditoren pivoxil (Brass « Jisposition and miotic effects of ‘eliprolol pprrio be e for fiI rst-ppaa ss cyvttooc chrom Itraconazole increases but grapefruit 2003.73: 199-208 centrations of iprolol (Lilja et Duloxetine is both an inhibitor ‘hild TS (SKIN Pharmacokinetics, safe effic of bose ntan a itadl with pulmonary arterial hypertension (Barst et al ‘iprofioxacin Effects of three fluoroquinolone single doses (Noel et al). 2003;7 salthy subjects (¢ ‘isapride irolinska cocktail Cisapride zymes (Christens ‘isplatin Cisplatin entrations Debrisoquin emboli6z ation in patients Nitin OF al cancer The Karolinska cock enzymes Clinical Pharmacology & Therapeutics Delayed-action preparations Clinical Pharmacology & Therapeutics an lation analyses of sustained (Commentary ) Concern about si nd smoking (Kar Clinical trial Hypothesis: a single clinical tria sufficient drug approval Developing countries tary) : Diesiiertes The need to consider the cost factor of drugs in clinical trials (Reider : ae 2003:73:477-8 (Let action (Quick Pharmacokinetics, safety, and efficacy of b osentan Diabetes mellitus, non-insulin-dependent with pulmonary arterial hypertension (Barst et al). 2003:73:372-82 \ study to sur susceptible Clopidogrel ssociated Clopidogrel b not aspirin reduces P-se tin expression and formation of mellitus (W platelet leukocyte aggre ates in patients with atherosclerotic vaissccuull ar Digoxin disease (Klinkhardt et al). 2003;7 Commentaries Commentaries. 2003;7 387-96, 481-90 Corrections Wandel et al) A comparison of three me thods for predicting lithium doses in Chinese P-glycoprotein—mediated intestina psychiatric patients (Chang et al) (2003:7 3:P88). 2003:7 3:565 Drescher et al). 2003 Effects « f nelfinavir and its M8 1 netabolite on lymphocy te P-glyc protein )kinetic and pharmaceutic activity during antiretroviral tthh erapy (Donahue et al) (2003;73:78 86 mophor RH40 (Tayrouz et al) 2003:73:576 Teriparatide h is no effect on the c Pharmacodynamic mode ng of the electroencephalographic eriect ts and V«¢ flumazenil in healthy volunteers se lated vith midazolam (Lemmens et Dipyridamole al) (1995;58:567-82). 2003 Dipyridamole enhances Correspondence; see Letters to the Editor tion ( >rstuyit et al) 2003:7 Cost of drugs; see Drug costs Dose-response relationship, drug Cremophor; see Castor oil Effect of hepatic impairment on the pharmacokinetics ¢ oT atomoxetine Cyclooxygenase; see Prostaglandin-endoperoxide synthase its metabolites (Chalon et al). 2003 CLINICAL PHARMACOLOGY & THERAPEUTICS 586 Subject index JUNE 2003 Effect of simultaneous versus staggered dosing on pharmacokinetic inter actions of protease inhibitors (Washington et al). 2003;:73:406-16 Efavirenz Effect of single and repeated oral doses of telithromycin on cardiac QT Population pharmacokinetics and effects of efavirenz in patients with interval in healthy subjects (Démolis et al). 2003;73:242-52 human immunodeficiency virus infection (Csajka et al). 2003;73:20-30 Effects of three fluoroquinolones on QT interval in healthy adults after Effectiveness of treatment; see Treatment outcome single doses (Noel et al). 2003;73:292-303 Electrocardiography Exposure-response analysis of pregabalin add-on treatment of patients with Effect of single and repeated oral doses of telithromycin on cardiac QT refractory partial seizures (Miller et al). 2003;73:491-505 interval in healthy subjects (Démolis et al). 2003;73:242-52 A rational approach for selection of optimal covariate-based dosing strat Effects of three fluoroquinolones on QT interval in healthy adults after egies (JGnsson and Karlsson). 2003;73:7-19 single doses (Noel et al). 2003;73:292-303 Drug approval Embolization, therapeutic Hypothesis: a single clinical trial plus causal evidence of effectiveness is Cisplatin tumor concentrations after intra-arterial cisplatin infusion or sufficient for drug approval (Peck et al). 2003;73:481-90 (Commen- embolization in patients with oral cancer (Tegeder et al). 2003;73: tary) 417-26 Drug costs End-stage renal disease; see Kidney failure, chronic Ensuring access to essential medicines in the developing countries: a Enzymes framework for action (Quick). 2003;73:279-83 (Commentary) The Karolinska cocktail for phenotyping of five human cytochrome P450 The need to consider the cost factor of drugs in clinical trials (Reidenberg) enzymes (Christensen et al). 2003;7 3:517 28 2003;73:477-8 (Letter) Essential drugs; see Drugs, essential What has been the impact of the concept of essential drugs? (Levy and Etanercept Reidenberg). 2003;73:2h7n 5-8 (Commentary) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis (Lee et al). 2003;73:348-65 Drug design Ethics Use of biomarkers from drug discovery through clinical practice: report of Use of healthy children as volunteers in drug studies: the ethical debate the Ninth European Federation of Pharmaceutical Sciences Conference (Koren et al). 2003;73:147-52 (Commentary) on Optimizing Drug Development (Rolan et al). 2003;73:284-91 Ethnic groups (Commentary ) Medical practice, race, and drug use (Kalow). 2003;73:132-4 (Letter) Drug interactions Excipients Coordinate induction of both cytochrome P4503A and MDR1 by St John’s “Inactive” excipients such as Cremophor can affect in vivo drug disposi- wort in healthy subjects (Dresser et al). 2003;73:41-50 tion (Wandel et al). 2003;73:394-6 (Commentary) Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibi F iion ‘Verstuyft et al). 2003;73:51-60 Effect of simultaneous versus staggered dosing on pharmacokinetic inter- Fexofenadine actions of protease inhibitors (Washington et al). 2003;73:406-16 Coordinate induction of both cytochrome P4503A and MDRI by St John’s Genetic variation in cyclooxygenase |: effects on response to aspirin wort in healthy subjects (Dresser et al). 2003;73:41-50 (Halushka et al). 2003;73:122-30 First week of life; see Infant, newborn “Inactive” excipients such as Cremophor can affect in vivo drug disposi- Fluoxetine tion (Wandel et al). 2003;73:394-6 (Commentary) Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lacta- Isozyme-specific induction of low-dose aspirin on cytochrome P450 in tion (Heikkinen et al). 2003;73:330-7 healthy subjects (Chen et al). 2003;73:264-71 Pharmacokinetic and pharmaceutic interaction between digoxin and Cre G mophor RH40 (Tayrouz et al). 2003;73:397-405 Gemfibrozil Steady-state pharmacokinetic interaction of modified-dose indinavir and Gemfibrozil increases plasma pravastatin concentrations and reduces prav- rifabutin (Hamzeh et al). 2003;73:159-69 astatin renal clearance (Kyrklund et al). 2003;73:538-44 Teriparatide has no effect on the calcium-mediated pharmacodynamics of Genes digoxin (Benson and Voelker). 2003;73:87-94 Coordinate induction of both cytochrome P4503A and MDRI by St John’s Drug labeling wort in healthy subjects (Dresser et al). 2003;73:41-50 Drug labeling should be kept current (Rajpal and Reidenberg). 2003;73:4-6 Polymorphisms in the CYP/A2 gene and theophylline metabolism in (Commentary) patients with asthma (Obase et al). 2003;73:468-74 Drug monitoring Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: con Routine early therapeutic drug monitoring is necessary during the first sequences for pravastatin pharmacokinetics (Nishizato et al). 2003;73 554-65 week of life (Stolk and Guillaume) (Letter); (de Hoog et al) (Reply) Genetics 2003:73:131-2 A study to survey susceptible genetic factors responsible for troglitazone- Drug studies; see Research associated hepatotoxicity in Japanese patients with type 2 diabetes Drug therapy mellitus (Watanabe et al). 2003;73:435-55 Drug therapy in the elderly: improving quality and access (Simon and Genome Gurwitz). 2003;73:387-93 (Commentary) Population differences in S-warfarin metabolism between CYP2C9 geno Drug utilization type—matched Caucasian and Japanese patients (Takahashi et al) Medical practice, race, and drug use (Kalow). 2003;73:132-4 (Letter) 2003:73:253-63 Drugs, essential Genotype Ensuring access to essential medicines in the developing countries: a Population differences in S-warfarin metabolism between CYP2C9 geno- framework for action (Quick). 2003;73:279-83 (Commentary) type—matched Caucasian and Japanese patients (Takahashi et al) What has been the impact of the concept of essential drugs? (Levy and 2003;73:253-63 Reidenberg). 2003;73:275-8 (Commentary) Glucuronates Duloxetine Analgesic effects of morphine and morphine-6-glucuronide in a transcu- Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in taneous electrical pain model in healthy volunteers (Skarke et al). healthy volunteers (Skinner et al). 2003;73:170-7 2003:73:107-21